GSE121788
Omeprazole regulates miRNA, mRNA and lncRNA networks revealed by RNA deep-sequencing  in Barrett's Esophagus
Recent clinical studies indicated Proton-pump inhibitors (PPIs) but not H2 Receptor Antagonists were associated with a decreased risk of esophageal adenocarcinoma. We'd like to clarify whether PPIs interfere with Barrett's esophagus(BE) pathogenesis during BE treatment and explore the novel roles of omeprazole beyond acid suppression. RNA deep-sequencing was conducted in BE organoids exposed to periodic bile acids(400µM, pH 5.5) stimulation with or without omeprazole(40µM)treatment. A total of 129 long non-coding RNAs, 20 microRNAs, and 285 mRNAs were significantly regulated. Then, bioinformatics tools and databases were employed to explore the potential functions and relationships of these RNAs. Our data showed that the most significantly involved pathways modulated by omeprazole were Phenylalanine metabolism and Glycosaminoglycan biosynthesis - keratan sulfate. In addition, the miRNA-mRNA-lncRNA network regulated by omeprazole was constructed. We have demonstrated some novel acid-independent mechanisms of omeprazole that might yield valuable insight into clinical management of BE, irrespective of acid reflux symptoms. Overall design: RNA deep-sequencing was conducted in BE organoids exposed to periodic bile acids (400µM, pH 5.5) stimulation with or without omeprazole (40µM) treatment.